Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Aprea Therapeutics, Inc. filed a Current Report on Form 8-K dated February 10, 2023. The filing reports a corporate action affecting the company’s common stock; it does not provide financial results for a reporting period.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
The company’s common stock trades under the symbol APRE on the Nasdaq Global Select Market.
Material Changes
- The company completed a one-for-twenty reverse stock split of its common stock, effective at 5:00 p.m. on February 10, 2023.
- At 7:50 p.m. on February 10, 2023, Nasdaq halted trading in the common stock pending release of material news related to the reverse split.
- Nasdaq informed the company that the halt was administrative, intended to allow market vendors to adjust for the reverse split.
- Trading was expected to resume at 9:45 a.m. on February 14, 2023.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance or operating outlook. The temporary trading halt and reverse split are the principal unusual items disclosed. The filing does not describe any additional risks, contingencies, or anticipated effects on the company’s operations or financial condition.
Facts Investors Should Verify
- Confirm the post-split share count, adjusted trading price, and any changes to outstanding securities or equity awards.
- Verify that Nasdaq trading resumed as expected on February 14, 2023.
- Review subsequent filings for the reverse split’s effect on capitalization, financing activities, and compliance with Nasdaq listing requirements.
- Note that the filing was signed on February 13, 2023, although the reported event date was February 10, 2023.